Pharmacy Times
JUNE 29, 2023
The impact of pharmacist on reducing medication expenses cannot be overstated as they leverage their medication management expertise within hospital settings through collaboration with the 340B program.
Fierce Healthcare
JUNE 28, 2023
Calm Health, the mental health offering of meditation app Calm, is tapping the Mayo Clinic to help design digital mental health programs to help cancer patients manage anxiety, depression and menta | The upcoming digital mental health program will be available to Calm Health customers and “will be designed for all adults with cancer,” according to the announcement.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JUNE 29, 2023
The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.
Drug Topics
JUNE 29, 2023
Although biosimilars have been introduced with the aim of competing with expensive biologic therapies, their adoption has been more gradual than expected.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmExec
JUNE 29, 2023
Venture designed to streamline drug development and clinical trials.
Drug Topics
JUNE 28, 2023
Researchers of a new paper discuss the inconsistencies between gene and cell therapy indications and payor coverage.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JUNE 27, 2023
Race, ethnicity, years after diagnosis and mental and physical stress are among factors associated with unmet supportive care needs and a higher risk of hospitalization among patients with cancer.
Fierce Healthcare
JUNE 28, 2023
Companies continue to ramp up investments in resources to support employees' mental health and wellbeing as workers grapple with work-related stress, burnout, depression and anxiety. | Digital mental health company Headspace is building on its partnership with Virgin Pulse to make it easier for employers and health plans to provide a range of mental health resources to their employees and plan members.
Pharmacy Times
JUNE 28, 2023
The growing volume of drugs sold through illegal online pharmacies are estimated to generate 10 times higher adverse event rates than drugs sold through legal pharmacies.
Drug Topics
JUNE 29, 2023
The approval was based on safety and efficacy data from 30 participants in 2 open-label, single-arm studies that received 1 to 3 infusions of donislecel.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PhRMA
JUNE 26, 2023
Earlier this month, 62 researchers from our member companies came to Washington, DC to meet with congressional offices during our annual fly-in event. This year included a record-breaking number of meetings — 145 over the course of the day.
PharmaVoice
JUNE 30, 2023
Vacation is calling, but so are patients. Here's how the industry adjusts in the summer.
Pharmacy Is Right For Me
JUNE 30, 2023
Join us as we explore the inspiring journey of Cayden Miller, a passionate pharmacy graduate from Southern Illinois University at Edwardsville School of Pharmacy. Cayden’s experience as a member of the LGBTQIA+ community has shaped his path in pharmacy, driving him to become an advocate for diversity, equity, and inclusion (DEI) within the profession.
Drug Topics
JUNE 28, 2023
Employing AI-driven technology ensures accurate and timely compliance with industry regulations, mitigates audits and fines, and helps forecast accurate reimbursements.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PhRMA
JUNE 27, 2023
On May 11th of this year, the COVID-19 national public health emergency (PHE) officially ended, marking an incredible milestone in the fight against COVID-19. While the end of the PHE signals a new chapter in the fight against COVID-19, the biopharmaceutical industry’s work continues to ensure our health care system is well-prepared for any curve balls this virus might throw as well as staying ahead of the next pandemic.
PharmaVoice
JUNE 29, 2023
From AI to diversity and decentralized trials, here’s how clinical trial operations are evolving.
STAT
JUNE 27, 2023
WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices. Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not.
Drug Topics
JUNE 26, 2023
At the state level, medication treatment rates ranged from 17.7% in Kansas to 82.8% in Maine.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JUNE 30, 2023
The new RSV vaccines are expected to be available in fall 2023.
PharmaVoice
JUNE 29, 2023
Transgender and nonbinary patients suffer more adverse health outcomes than the general population, yet are often underrepresented in clinical research. Now, there’s momentum to change the status quo.
STAT
JUNE 26, 2023
SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing giant Illumina has begun to lay off 10% of its research and development team, according to internal emails obtained and reviewed by STAT. The layoffs, which began last Wednesday, impact research teams across the company’s California sites in San Diego and Foster City, as well as locations in Madison, Wisconsin; Singapore; and the United Kingdom.
Drug Topics
JUNE 30, 2023
With high-deductible health plans on the rise, pharmacists need a cash pricing plan now. Artificial intelligence, or AI, could be the answer. Learn more about this innovative technology and how it could impact your bottom line.
Pharmacy Times
JUNE 30, 2023
Valoctocogene roxaparvovec-rvox (Roctavian; BioMarin) is a one-time gene therapy product administered as a single dose by intravenous infusion for hemophilia A.
PharmaVoice
JUNE 26, 2023
Based on real-world data from patients in China, researchers were able to pinpoint factors that led to recurring infections — and which drug combos helped.
STAT
JUNE 25, 2023
SAN DIEGO — The American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease, an increasingly prevalent condition that can lead to serious liver damage. There are no approved medications for the disease, but among available diabetes drugs, the ADA singled out GLP-1 treatments as an option doctors could consider, according to recommendations published during the annual ADA conference.
Drug Topics
JUNE 30, 2023
Disadvantaged groups are feeling the sting of health care costs—so much so that many are foregoing health care because they can’t pay for it.
Pharmacy Times
JUNE 30, 2023
Independent pharmacies can provide more personalized care to individuals with behavioral health conditions or intellectual and developmental disabilities.
PharmaVoice
JUNE 28, 2023
Although DEI efforts have ramped up, the industry is still searching for proven ways to get results.
STAT
JUNE 30, 2023
The five cases of malaria diagnosed in Florida and Texas in recent weeks — the first cases of local transmission in the United States in 20 years — have worried some residents and led state and federal officials to issue public alerts about the cluster of infections. But scientists and public health officials, while advising people in the affected areas to take precautions, say there is little cause for alarm, for several reasons: The number of cases is very low; there are easy, lo
Drug Topics
JUNE 30, 2023
The acceptance comes 5 days after the agency approved delandistrogene moxeparvovec-rokl to treat ambulatory pediatric DMD patients aged 4 to 5 years.
Pharmacy Times
JUNE 28, 2023
Evidence shows vitamin D deficiency is linked to abnormal dopamine signaling disorders in neurodevelopment, including schizophrenia.
PharmaVoice
JUNE 27, 2023
Intercept Pharmaceuticals has stepped out of the race to the first U.S. approved treatment for the complicated liver disease NASH, leaving room for other pharmas to get their foot in the door.
Pharmaceutical Technology
JUNE 26, 2023
After Intercept’s Ocaliva rejection, multiple companies are taking aim at becoming the first US-approved NASH therapy.
Expert insights. Personalized for you.
123 
Let's personalize your content